BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zeng C, Wang YL, Xie C, Sang Y, Li TJ, Zhang M, Wang R, Zhang Q, Zheng L, Zhuang SM. Identification of a novel TGF-β-miR-122-fibronectin 1/serum response factor signaling cascade and its implication in hepatic fibrogenesis. Oncotarget 2015;6:12224-33. [PMID: 25909171 DOI: 10.18632/oncotarget.3652] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Lambrecht J, Mannaerts I, van Grunsven LA. The role of miRNAs in stress-responsive hepatic stellate cells during liver fibrosis. Front Physiol. 2015;6:209. [PMID: 26283969 DOI: 10.3389/fphys.2015.00209] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
2 Yin R, Guo D, Zhang S, Zhang X. miR-706 inhibits the oxidative stress-induced activation of PKCα/TAOK1 in liver fibrogenesis. Sci Rep 2016;6:37509. [PMID: 27876854 DOI: 10.1038/srep37509] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
3 Sendi H, Mead I, Wan M, Mehrab-Mohseni M, Koch K, Atala A, Bonkovsky HL, Bishop CE. miR-122 inhibition in a human liver organoid model leads to liver inflammation, necrosis, steatofibrosis and dysregulated insulin signaling. PLoS One. 2018;13:e0200847. [PMID: 30024933 DOI: 10.1371/journal.pone.0200847] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
4 Ding H, Xu Y, Jiang N. Upregulation of miR-101a Suppresses Chronic Renal Fibrosis by Regulating KDM3A via Blockade of the YAP-TGF-β-Smad Signaling Pathway. Mol Ther Nucleic Acids 2020;19:1276-89. [PMID: 32092824 DOI: 10.1016/j.omtn.2020.01.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
5 Wu Z, Huang S, Zheng X, Gu S, Xu Q, Gong Y, Zhang J, Fu B, Tang L. Regulatory long non-coding RNAs of hepatic stellate cells in liver fibrosis (Review). Exp Ther Med 2021;21:351. [PMID: 33732324 DOI: 10.3892/etm.2021.9782] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yu F, Jiang Z, Chen B, Dong P, Zheng J. NEAT1 accelerates the progression of liver fibrosis via regulation of microRNA-122 and Kruppel-like factor 6. J Mol Med (Berl) 2017;95:1191-202. [PMID: 28864835 DOI: 10.1007/s00109-017-1586-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 8.4] [Reference Citation Analysis]
7 Qin XJ, Zhang JX, Wang RL. Exosomes as mediators and biomarkers in fibrosis. Biomark Med 2020;14:697-712. [PMID: 32643390 DOI: 10.2217/bmm-2019-0368] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Cai R, Qimuge N, Ma M, Wang Y, Tang G, Zhang Q, Sun Y, Chen X, Yu T, Dong W, Yang G, Pang W. MicroRNA-664-5p promotes myoblast proliferation and inhibits myoblast differentiation by targeting serum response factor and Wnt1. J Biol Chem 2018;293:19177-90. [PMID: 30323063 DOI: 10.1074/jbc.RA118.003198] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
9 Mahdinloo S, Kiaie SH, Amiri A, Hemmati S, Valizadeh H, Zakeri-Milani P. Efficient drug and gene delivery to liver fibrosis: rationale, recent advances, and perspectives. Acta Pharm Sin B 2020;10:1279-93. [PMID: 32874828 DOI: 10.1016/j.apsb.2020.03.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
10 Tian Y, Zhong L, Gao S, Yu Y, Sun D, Liu X, Ji J, Yao Y, Liu Y, Jiang Z. LncRNA LINC00974 Downregulates miR-122 to Upregulate RhoA in Oral Squamous Cell Carcinoma. Cancer Biotherapy and Radiopharmaceuticals 2021;36:18-22. [DOI: 10.1089/cbr.2019.2907] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
11 Gong J, Wang ZX, Liu ZY. miRNA‑1271 inhibits cell proliferation in neuroglioma by targeting fibronectin 1. Mol Med Rep 2017;16:143-50. [PMID: 28535003 DOI: 10.3892/mmr.2017.6610] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
12 Wu J, Huang J, Kuang S, Chen J, Li X, Chen B, Wang J, Cheng D, Shuai X. Synergistic MicroRNA Therapy in Liver Fibrotic Rat Using MRI-Visible Nanocarrier Targeting Hepatic Stellate Cells. Adv Sci (Weinh) 2019;6:1801809. [PMID: 30886803 DOI: 10.1002/advs.201801809] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
13 Ding Z, Lin J, Sun Y, Cong S, Liu S, Zhang Y, Chen Q, Chen J. miR‐122‐5p negatively regulates the transforming growth factor‐β/Smad signaling pathway in skeletal muscle myogenesis. Cell Biochem Funct 2020;38:231-8. [DOI: 10.1002/cbf.3460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Schueller F, Roy S, Vucur M, Trautwein C, Luedde T, Roderburg C. The Role of miRNAs in the Pathophysiology of Liver Diseases and Toxicity. Int J Mol Sci. 2018;19:pii: E261. [PMID: 29337905 DOI: 10.3390/ijms19010261] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 13.0] [Reference Citation Analysis]
15 Yue B, Li H, Liu M, Wu J, Li M, Lei C, Huang B, Chen H. Characterization of lncRNA-miRNA-mRNA Network to Reveal Potential Functional ceRNAs in Bovine Skeletal Muscle. Front Genet 2019;10:91. [PMID: 30842787 DOI: 10.3389/fgene.2019.00091] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
16 Sekiba K, Otsuka M, Ohno M, Yamagami M, Kishikawa T, Suzuki T, Ishibashi R, Seimiya T, Tanaka E, Koike K. Hepatitis B virus pathogenesis: Fresh insights into hepatitis B virus RNA. World J Gastroenterol 2018; 24(21): 2261-2268 [PMID: 29881235 DOI: 10.3748/wjg.v24.i21.2261] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
17 Roy S, Trautwein C, Luedde T, Roderburg C. A General Overview on Non-coding RNA-Based Diagnostic and Therapeutic Approaches for Liver Diseases. Front Pharmacol 2018;9:805. [PMID: 30158867 DOI: 10.3389/fphar.2018.00805] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
18 Fabregat I, Moreno-càceres J, Sánchez A, Dooley S, Dewidar B, Giannelli G, ten Dijke P; the IT-LIVER Consortium. TGF-β signalling and liver disease. FEBS J 2016;283:2219-32. [DOI: 10.1111/febs.13665] [Cited by in Crossref: 247] [Cited by in F6Publishing: 243] [Article Influence: 41.2] [Reference Citation Analysis]
19 Abdelsalam L, Ibrahim AA, Shalaby A, Osman N, Hashad A, Badawy D, Elghobary H, Amer E. Expression of miRNAs-122, -192 and -499 in end stage renal disease associated with acute myocardial infarction. Arch Med Sci 2019;15:1247-53. [PMID: 31572470 DOI: 10.5114/aoms.2019.87095] [Reference Citation Analysis]
20 Wu J, Han M, Li J, Yang X, Yang D. Immunopathogenesis of HBV Infection. In: Tang H, editor. Hepatitis B Virus Infection. Singapore: Springer; 2020. pp. 71-107. [DOI: 10.1007/978-981-13-9151-4_4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
21 You K, Li SY, Gong J, Fang JH, Zhang C, Zhang M, Yuan Y, Yang J, Zhuang SM. MicroRNA-125b Promotes Hepatic Stellate Cell Activation and Liver Fibrosis by Activating RhoA Signaling. Mol Ther Nucleic Acids. 2018;12:57-66. [PMID: 30195793 DOI: 10.1016/j.omtn.2018.04.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
22 Nozari E, Moradi A, Samadi M. Effect of Atorvastatin, Curcumin, and Quercetin on miR-21 and miR-122 and their correlation with TGFβ1 expression in experimental liver fibrosis. Life Sciences 2020;259:118293. [DOI: 10.1016/j.lfs.2020.118293] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
23 Tan Z, Sun H, Xue T, Gan C, Liu H, Xie Y, Yao Y, Ye T. Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy. Front Cell Dev Biol 2021;9:730176. [PMID: 34621747 DOI: 10.3389/fcell.2021.730176] [Reference Citation Analysis]
24 Navarrete F, Wong YS, Cabezas J, Riadi G, Manríquez J, Rojas D, Furlanetto Mançanares AC, Rodriguez-Alvarez L, Saravia F, Castro FO. Distinctive Cellular Transcriptomic Signature and MicroRNA Cargo of Extracellular Vesicles of Horse Adipose and Endometrial Mesenchymal Stem Cells from the Same Donors. Cell Reprogram 2020;22:311-27. [PMID: 32991224 DOI: 10.1089/cell.2020.0026] [Reference Citation Analysis]
25 Li J, Li S. Reply to: "miR-122 expression is not regulated during activation of hepatic stellate cells". J Hepatol 2016;65:868. [PMID: 27388922 DOI: 10.1016/j.jhep.2016.06.020] [Reference Citation Analysis]
26 Zhang J, Zhao Z, Bai H, Jiao L, Wu Q, Wu T, Liu T, Hu X, Song J, Lyv M, Ying B. The Variant at TGFBRAP1 but Not TGFBR2 Is Associated with Antituberculosis Drug-Induced Liver Injury. Evid Based Complement Alternat Med 2019;2019:1685128. [PMID: 31534460 DOI: 10.1155/2019/1685128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
27 Kitano M, Bloomston PM. Hepatic Stellate Cells and microRNAs in Pathogenesis of Liver Fibrosis. J Clin Med. 2016;5. [PMID: 26999230 DOI: 10.3390/jcm5030038] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 10.3] [Reference Citation Analysis]
28 Riester SM, Arsoy D, Camilleri ET, Dudakovic A, Paradise CR, Evans JM, Torres-Mora J, Rizzo M, Kloen P, Julio MK, van Wijnen AJ, Kakar S. RNA sequencing reveals a depletion of collagen targeting microRNAs in Dupuytren's disease. BMC Med Genomics 2015;8:59. [PMID: 26446724 DOI: 10.1186/s12920-015-0135-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
29 Kim KH, Lee JI, Kim OH, Hong HE, Kwak BJ, Choi HJ, Ahn J, Lee TY, Lee SC, Kim SJ. Ameliorating liver fibrosis in an animal model using the secretome released from miR-122-transfected adipose-derived stem cells. World J Stem Cells 2019; 11(11): 990-1004 [PMID: 31768225 DOI: 10.4252/wjsc.v11.i11.990] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
30 Zhou L, Liu S, Han M, Ma Y, Feng S, Zhao J, Lu H, Yuan X, Cheng J. miR-185 Inhibits Fibrogenic Activation of Hepatic Stellate Cells and Prevents Liver Fibrosis. Mol Ther Nucleic Acids 2018;10:91-102. [PMID: 29499960 DOI: 10.1016/j.omtn.2017.11.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
31 Han JH, Kim OH, Lee SC, Kim KH, Park JH, Lee JI, Lee KH, Hong HE, Seo H, Choi HJ, Ju JH, Kim SJ. A Novel Hepatic Anti-Fibrotic Strategy Utilizing the Secretome Released from Etanercept-Synthesizing Adipose-Derived Stem Cells. Int J Mol Sci 2019;20:E6302. [PMID: 31847135 DOI: 10.3390/ijms20246302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Shaker OG, Senousy MA. Serum microRNAs as predictors for liver fibrosis staging in hepatitis C virus-associated chronic liver disease patients. J Viral Hepat. 2017;24:636-644. [PMID: 28211229 DOI: 10.1111/jvh.12696] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
33 Zhao Z, Lin CY, Cheng K. siRNA- and miRNA-based therapeutics for liver fibrosis. Transl Res 2019;214:17-29. [PMID: 31476281 DOI: 10.1016/j.trsl.2019.07.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
34 Fiore EJ, Domínguez LM, Bayo J, García MG, Mazzolini GD. Taking advantage of the potential of mesenchymal stromal cells in liver regeneration: Cells and extracellular vesicles as therapeutic strategies. World J Gastroenterol 2018; 24(23): 2427-2440 [PMID: 29930465 DOI: 10.3748/wjg.v24.i23.2427] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
35 Lauschke VM, Mkrtchian S, Ingelman-Sundberg M. The role of microRNAs in liver injury at the crossroad between hepatic cell death and regeneration. Biochem Biophys Res Commun 2017;482:399-407. [PMID: 27789285 DOI: 10.1016/j.bbrc.2016.10.084] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
36 Zeng C, Sang Y, Wang FY, Zhuang SM. Opposing roles of C/EBPα and eEF1A1 in Sp1-regulated miR-122 transcription. RNA Biol 2020;17:202-10. [PMID: 31561740 DOI: 10.1080/15476286.2019.1673656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
37 Catapano F, Scaglioni D, Maresh K, Ala P, Domingos J, Selby V, Ricotti V, Phillips L, Servais L, Seferian A, Groot I, Krom YD, Voit T, Verschuuren JJGM, Niks EH, Straub V, Morgan J, Muntoni F. Novel free-circulating and extracellular vesicle-derived miRNAs dysregulated in Duchenne muscular dystrophy. Epigenomics 2020;12:1899-915. [PMID: 33215544 DOI: 10.2217/epi-2020-0052] [Reference Citation Analysis]
38 Li Y, Liu P, Wei F. Long non‑coding RNA MBI‑52 inhibits the development of liver fibrosis by regulating the microRNA‑466g/SMAD4 signaling pathway. Mol Med Rep 2022;25:33. [PMID: 34850963 DOI: 10.3892/mmr.2021.12549] [Reference Citation Analysis]
39 Lou G, Yang Y, Liu F, Ye B, Chen Z, Zheng M, Liu Y. MiR-122 modification enhances the therapeutic efficacy of adipose tissue-derived mesenchymal stem cells against liver fibrosis. J Cell Mol Med. 2017;21:2963-2973. [PMID: 28544786 DOI: 10.1111/jcmm.13208] [Cited by in Crossref: 77] [Cited by in F6Publishing: 82] [Article Influence: 15.4] [Reference Citation Analysis]